Nelly Friedrichsen

Medicine & Life Sciences

1. Alzheimer Disease 100%
2. Amyloid 75%
3. 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole 53%
4. gantenerumab 32%
5. White Matter 29%
6. Biomarkers 29%
7. Positron-Emission Tomography 26%
8. solanezumab 23%
9. Atrophy 22%
10. florbetapir 21%
11. Mutation 21%
12. Cognitive Dysfunction 16%
13. Cerebrospinal Fluid 15%
14. Dementia 14%
15. Brain 14%
16. Cross-Sectional Studies 13%
17. Amyloid Plaques 13%
18. Cheirogaleidae 13%
19. Observational Studies 10%
20. Longitudinal Studies 10%
21. Cerebral Amyloid Angiopathy 9%
22. Hoarding 9%
23. Disease Progression 9%
24. Spastic Paraparesis 9%
25. Presenilin-1 8%
26. Phosphorylation 8%
27. Parietal Lobe 8%
28. Apolipoprotein E4 8%
29. Neuroimaging 8%
30. Clinical Trials 7%
31. Choroid Plexus 7%
32. Phase III Clinical Trials 7%
33. Mental Status and Dementia Tests 7%
34. Primates 7%
35. Machine Learning 6%
36. Temporal Lobe 6%
37. Intermediate Filaments 6%
38. Parkinsonian Disorders 6%
39. Internal Carotid Artery 6%
40. Apolipoproteins E 6%
41. Down Syndrome 6%
42. Cognition 6%
43. Streptozocin 6%
44. Pathology 6%
45. Wounds and Injuries 5%
46. Magnetic Resonance Imaging 5%
47. Cluster Analysis 5%
48. Immunization 5%
49. Lemur 5%